SCHEMBL5584830

SCHEMBL5584830

Cc1cc(-c2cc(CO)c(=O)n(CCCc3cccc(Cl)c3)n2)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
TP53 P04637 4/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PDE4A P27815 4/20 0.39
PDE4B Q07343 4/20 0.39
PDE4C Q08493 4/20 0.39
PDE4D Q08499 4/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
FPR1 P21462 1/20 0.36
FPR2 P25090 1/20 0.36
BRD4 O60885 1/20 0.36
LMNA P02545 1/20 0.36
MDM2 Q00987 1/20 0.35
CASR P41180 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5584116 0.89 TP53 (0.41) MAPTTP53POLBSMN1; SMN2PDE4A
SCHEMBL5584862 0.89 KMT2A (0.43) MAPTTP53PDE4BKMT2AMEN1
SCHEMBL5584807 0.87 MAPT (0.40) MAPTTP53PDE4APDE4BPDE4C
SCHEMBL5584920 0.86 PDE4B (0.41) MAPTTP53POLBSMN1; SMN2PDE4A
SCHEMBL5584809 0.86 PDE4A (0.37) MAPTTP53POLBSMN1; SMN2PDE4A
SCHEMBL5584480 0.86 ALDH1A1 (0.39) MAPTTP53POLBSMN1; SMN2PDE4A
SCHEMBL5584326 0.83 TP53 (0.43) MAPTTP53POLBSMN1; SMN2KMT2A
SCHEMBL5584378 0.82 MAPT (0.41) MAPTTP53KMT2AMEN1BRD4
SCHEMBL1925414 0.82 MEN1 (0.47) MAPTPOLBSMN1; SMN2PDE4APDE4B
SCHEMBL5585300 0.80 MAPT (0.46) MAPTPOLBSMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7211577-B2 Water-soluble phenylpyridazine derivative and medicine containing the same KOWA CO., LTD. (JP) 2007-05-01 US disclosed
US-20060142292-A1 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases KOWA CO., LTD. (JP) 2006-06-29 US disclosed
EP-1604984-A1 WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVE AND MEDICINE CONTAINING THE SAME Kowa Co., Ltd. (JP) 2005-12-14 EP disclosed
US-6861428-B2 Water-soluble phenylpyridazine compounds and compositions containing the same KOWA CO., LTD. (JP) 2005-03-01 US disclosed
US-20040002497-A1 Water-soluble phenylpyridazine compounds and compositions containing the same KOWA CO., LTD. (JP) 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142292-A1 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases IL1B, IL1A, IL1R1 MAPT 2720/4885TP53 1443/4885POLB 1602/4885
US-20040002497-A1 Water-soluble phenylpyridazine compounds and compositions containing the same IL1A, IL1B, IL1R1 MAPT 4306/4885TP53 1226/4885POLB 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.